GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Related Disparities in Mortality Among Young Adults With Type 2 Diabetes" underscores the need for addressing disparities in ...

Saving hearts, one beat at a time Heart attacks are a leading cause of death and disability in Europe, and their effects ...

Diabetic retinopathy (DR) affects about 26 percent of people with diabetes. While many patients have an early form of DR, the condition can progress, posing the threat of irreversible vision loss.

Taiwan says China sending largest naval fleet in years to region The Saudi Arabia diabetes drug market is a vital segment of the pharmaceutical industry, catering to the needs of a significant portion ...

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a newer class of medications used to treat type 2 diabetes. These ...

According to a report by the Public Health Foundation of India, 25% of people with diabetes in India have a high risk of ...

Dapagliflozin and empagliflozin cut mortality from heart failure with reduced ejection fraction whether or not patients have ...

Advances in cardiovascular pharmacology have significantly enhanced patient outcomes through a new wave of medications ranging from anticoagulants and antiplatelet agents to lipid-lowering drugs and ...